Indivior Pharmaceuticals (INDV) Free Cash Flow (2024 - 2026)

Indivior Pharmaceuticals' Free Cash Flow history runs 3 years deep, the most recent figure standing at -$29.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 141.43% year-over-year to -$29.0 million in Q1 2026; TTM through Mar 2026 was -$192.0 million, a 265.52% decrease from a year earlier, with the FY2025 full-year figure at -$93.0 million, down 1428.57% from the prior year.
• Free Cash Flow improved to -$29.0 million in Q1 2026 per INDV's latest filing, from -$245.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $141.0 million in Q2 2025 and bottomed at -$245.0 million in Q4 2025.
• The 3-year median for Free Cash Flow is -$29.0 million (2026), against an average of -$12.8 million.
• Biggest YoY gain for Free Cash Flow was 279.49% in 2025; the steepest drop was 1080.0% in 2025.
• Year by year, Free Cash Flow stood at -$33.0 million in 2024, then slumped by 642.42% to -$245.0 million in 2025, then jumped by 88.16% to -$29.0 million in 2026.
• Per Business Quant, the three latest INDV Free Cash Flow figures stand at -$29.0 million (Q1 2026), -$245.0 million (Q4 2025), and -$59.0 million (Q3 2025).